Actively Recruiting
Multicenter Screening to Identify KIT D816V Mutation Prevalence in Patients Suspected of Clonal Mast Cell Disease
Led by Blueprint Medicines Corporation · Updated on 2026-10-07
750
Participants Needed
26
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter screening study to determine how common the KIT D816V mutation is among people suspected of having clonal mast cell disease. This study focuses on various groups, including those with symptoms of mast cell activation, certain related diseases, specific blood cancers, and skin mast cell involvement. Participants are divided into four cohorts based on their symptoms or diagnoses. The study involves collecting blood or bone marrow samples after informed consent and medical history review. The main goal is to detect the KIT D816V mutation in peripheral blood using advanced molecular techniques on the first day of participation. During the study, participants provide samples and relevant health information. Researchers measure the presence of the mutation using digital droplet PCR and a super rolling circle amplification assay. The study continues until July 2028, with follow-up evaluations focusing on mutation prevalence to better understand this condition.
CONDITIONS
Brief Title
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Research Team
B
Blueprint Medicines
B
Blueprint Medicines, EU Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here